Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis
Main finding · Seroconversion after third vaccination in previous non-respondersResult — go to the resultOdds ratio 3.66 95% CI 0.93–14.0Authors' conclusion
A once positive humoral response after COVID-19 vaccination persists irrespective of intercurrent RTX infusion.
Study context
- Population
- Patients with RA treated with (ultra-)low-dose rituximab (RTX) from the COVAC cohort; previous non-responders with humoral response measured 2–6 weeks after a third COVID-19 vaccination98 third vaccine analysis
- Participants
- 196 patients
- Exposure
- RTX 200 mg vs 500 mg vs 1000 mg latest dose before first vaccination
- 200 mg RTXn = 13
- 500 mg RTXn = 37
- 1000 mg RTXn = 48reference
- Outcome
- Seroconversion (positive humoral response) after a third COVID-19 vaccination
- Follow-up
- 2-6 weeks after third vaccination
Methodological detailsmonocentre, observational, univariable logistic regression
- Monocentre
- Observational
- Univariable logistic regression
Main finding
As reported in the abstract
Seroconversion after third vaccination in previous non-responders
Odds ratio
3.66
95% CI 0.93–14.0
Events by group
200 mgvs 1000 mg
OR 3.66 (95% CI 0.93–14.0)
- Overall third vaccination response
- 19/98 (19%)
- Later timing, per month since infusion: OR (95% CI 0.97, 1.35), non-significant trend
- 1.16
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | |
|---|---|---|
| Third vaccination response by timing, per month since infusionNon-significant trend | 1.16 (0.97–1.35) | |
| 0.512Odds ratio (log scale) |
Persistence of humoral response after two-dose vaccination · before third vaccination
- Persisted, all previous responders
- 96% (22/23)
- Persisted, patients who received RTX between the two measurements
- 89% (8/9)
Original publication
Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis. Rheumatology (Oxford). Published 24 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →